Interview with Philippe van der Hofstadt, Founder & CEO, B & C Group
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Address: Watson & Crick Hill, Rue Granbonpré 11, B-1348 Mont-Saint-Guibert,Belgium
Tel: +32 (0)10 237 444
Web: http://www.bnc-group.com/
B & C Group is a Packaging & Logistics Company solely dedicated to (Pre)Clinical Research.
Established in 1999 as a niche provider of ground transport for batched frozen specimen shipments, B & C was the first company of its kind to offer full specimen tracking and on-site data cleaning. Today we offer a unique combination of logistics services through our network.
B & C Group adds value to your clinical research logistics process by its unique approach on centralization and integration combined with experience, expertise and geographic reach.
Since January 2009, B & C Group has relocated its two sites in Mechelen and Wavre to the former Eli Lilly IMP Packaging & distribution facility in Mont-St-Guibert (South of Brussels – Belgium).
B & C provides integrated Packaging and Logistics services for the Clinical Trials sponsored or supported by:
Pharmaceutical Companies
Biotechnology Companies
Central Laboratories
Contract Research Organizations
Academic Institutions
Investigational Sites
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Belgium’s Flanders region is a hotbed of biotech excellence, with numerous examples of university spin-offs being translated into commercial-stage companies and many of those later acquired by Big Pharma. Wouter…
Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish…
Karel van de Sompel of GIBBIS – the pluralistic federation of the public and private social-profit healthcare sector within the Brussels area – outlines the scope and aims of the…
Benelux is a crucial cluster for Bristol Myers Squibb (BMS), which recently started construction of its first European CAR-T cell therapy production centre at the Leiden Bio Science Park. Sally…
Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far…
Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus…
Ahead of the much-discussed implementation of an EU-wide legislative framework on joint clinical assessments in 2025, Merck’s Nikola Vesic outlines the scope and aims of the reform and highlights some…
Belgium is a key country for Sanofi in Europe as home to its Geel production site, in which almost EUR one billion has been invested over the past 15 years,…
Stephan Van Nieuwenhove of Finnish national champion Orion Pharma outlines the company’s entrance into the Benelux markets, the significance of the recent acquisition of Belgian animal health firm Inovet BV,…
Diane Kleinermans leads the reimbursement commission at Belgium’s medicines payer, the National Institute for Health and Disability Insurance (NIHDI). With Belgium currently undergoing a landmark reform of its reimbursement procedure,…
Alexander Alonso, GM of medtech giant BD’s Benelux affiliate explains the impact of the COVID-19 pandemic on its operations, the company’s 2025 strategy, and some of the most significant recent…
See our Cookie Privacy Policy Here
